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Summary
Hepatitis type C is a major worldwide health problem. In Italy
injecting drug use, surgery/hospitalisation, dental treatments are
the most common risk factors among patients with hepatitis C.
HCV is efficiently transmitted parenterally but the risk of HCV
transmission by sexual or by vertical/perinatal route is low. As a
consequence of the implementation of anti-HCV screening and
the introduction of increasing restrictions on donor eligibility, the
frequency of transfusion-associated hepatitis C has significantly
declined during the past recent years. A candidate vaccine to pro-
tect against HCV is under development.
Hepatitis type C is a major worldwide public health
problem. 
Hepatitis C virus (HCV) infection can cause both acute
and chronic liver diseases and is also associated with
several extrahepatic manifestations, including cryoglob-
ulinemia, vasculitis, glomerulonephritis and peripheral
neurophaty. A strong association has also been found be-
tween chronic hepatitis C or HCV-related cirrhosis and
the development of primary hepatocellular carcinoma.
The global prevalence of chronic hepatitis C is estimat-
ed to average 3% (ranging from 0.1 to 5% in different
countries). Thus there are at least 150 million chronic
HCV carriers throughout the world, of whom an esti-
mated 4 million are in the USA and 5 million in Western
Europe. The prevalence seems to be higher in Eastern
Europe than in Western Europe. According to the data
reported at the EASL (European Association for the
Study of the Liver) International Consensus Conference
on Hepatitis C, in industrialised countries HCV ac-
counts for 20% of cases of acute hepatitis, 70% of cases
of chronic hepatitis, 40% of cases of end-stage cirrhosis,
60% of cases of hepatocellular carcinoma and 30% of
liver transplants 1.
The incidence of acute hepatitis C is currently estimated
to be 1-3 cases/100,000 persons annually. However,
since HCV infection goes often asymptomatic, the num-
ber of infected individuals per year is estimated to be at
least 10 fold higher than reported. Although the burden
of hepatitis C is still high, the incidence rate has dram-
matically declined in recent years. The incidence is
mainly declined for two reasons: 1) transmission by
blood and blood products has been reduced to near zero
as a consequence of the introduction of selective donor
criteria and testing for anti-HCV; 2) universal precau-
tions have markedly reduced viral transmission in med-
ical settings. Intravenous drug use remains the main
mode of transmission; but, even here, the rate of trans-
mission is diminishing due to a heightened awareness of
the risk of needle sharing and the availability, in some
countries, of needle-exchange program 1 2. 
In the last two decades the incidence of acute hepatitis has
declined progressively in Italy in response to improve-
ments in the general standards of hygiene and sanitation,
and to the introduction of several measures as the screen-
ing for safe blood and blood products, use of disposable
medical equipment and of appropriate disinfection and
sterilisation systems in medical setting. The actual inci-
dence rate of acute nonA-nonB hepatitis (majority he-
patitis type C) in our country is 1 case per 100,000 resi-
dents 3. The acute disease is more frequent among young
persons (age 15-24 years), in those living in southern Italy
or in the islands, and in male subjects than in females.
Modes of transmission 
Hepatitis C virus is efficiently transmitted parenterally,
as is shown by the high rates of anti-HCV positivity
among blood and blood product recipients, intravenous
drug users, hemodialysis patients and health care work-
ers with occupational exposure to blood. However, in a
significant portion (around 30-40%) of patients with
acute and chronic hepatitis C the source of infection re-
mains unidentified 4 5.
Several studies have been carried out in order to evalu-
ate the potential risk of HCV transmission by the verti-
cal/perinatal route, or the horizontal route (i.e. person to
person contact, either through sexual transmission or
daily household contact). Published data on these issues
are widely divergent, providing evidence both for and
against such modes of viral transmission 4-7.
As concern the sexual transmission, several studies have
shown that the prevalence of anti-HCV antibodies is sig-
nificantly higher in homosexuals and heterosexuals with
multiple partners, among prostitutes and their clients,
and among patients with sexually transmitted diseases
(STD) than in controls.
However, in interpreting these data possible bias cannot
be excluded since most published studies have included
intravenous drug users in their study population, and
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have used blood donors as controls (a highly selected
population not representative of the general population).
Other studies carried out on sexual partners of HCV in-
fected haemophiliacs and transfusion recipients have
shown little or no transmission of HCV. There is never-
theless general agreement that the risk of acquiring
HCV infection through sexual contact becomes much
higher when the carrier partner is co-infected with HIV.
In this setting it is likely that the immunodepression sec-
ondary to HIV infection favours HCV transmission to
the partner by increasing the viral load in the index case.
HCV vertical transmission is uncommon: the preva-
lence of transmission from mother to child is less than
6% 7. The risk of transmission appears to be greater in
women with high levels of HCV viremia or HIV co-in-
fection. The mode of delivery (caesarean section/vagi-
nal) does not appear to influence the rate of HCV trans-
mission from mother to child. There is no association
between breast-feeding and transmission of HCV infec-
tion from mother to child.
Nosocomial transmission of HCV, like that of other
blood-borne pathogens, is well documented. In devel-
oped countries this is not a major source of HCV infec-
tion, except among hematologic patients under im-
munosoppressive therapy and patients on chronic he-
modialysis where 30-70% are infected 2. However,
nosocomial transmission of HCV appears to be a major
source of infection in many developing countries due to
possible transfusions of blood from unselected donors
and the use of contaminated or unproprerly sterilised
surgical and medical equipments and the re-use of sy-
ringes and needles. 
Prevention measures
In recent decades the frequency of transfusion-associat-
ed hepatitis C has progressively dropped as a conse-
quence of the introduction of increasing restrictions on
donor eligibility and of specific (anti-HCV) assays to
detect HCV carriers. Donors screening and the virucidal
treatment of blood products such as the factor VIII and
IX used to treat haemophiliacs, have proved effective
measures to minimise the residual risk of infection
through the transfusion of blood or its derivates.
In the health care settings, the safety procedures adopt-
ed to avoid infection with blood-borne viruses like HIV
and HBV, are also effective in preventing HCV trans-
mission 8.
Since parenteral drug injection is one of the major risk
factors in acquiring HCV infection, extensive education
campaigns aimed at persuading young persons to avoid
drugs or at least to avoid syringes and needles sharing
are needed.
The use of condoms in stable monogamous relation-
ships is not strictly recommended but is strongly en-
couraged in patients with multiple partners 1.
A study carried out in Italy, showed the efficacy of pro-
phylaxis with intramuscolar immune serum globulin in
preventing sexual transmission of HCV 9.
The high degree of genetic heterogeneity of the enve-
lope proteins of HCV represents a serious hurdle in the
development of an effective vaccine. However, a candi-
date vaccine which employs the full-length gpE1/gpE2
has already been produced and injected in chimpanzees,
with promising results in terms of safety and efficacy 10.
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